# Trial to Evaluate the Safety and Immunogenicity of Priming Regimens of 426c.Mod.Core-C4b and Optional Boost Regimen With HIV Trimer BG505 SOSIP.GT1.1 gp140, Both Adjuvanted With 3M-052-AF + Alum in Healthy, Adult Participants Without HIV

> **NCT05471076** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 52 (actual)

## Conditions studied

- HIV-1-infection

## Interventions

- **BIOLOGICAL:** 426c.Mod.Core-C4b 30 mcg
- **BIOLOGICAL:** 426c.Mod.Core-C4b 100 mcg
- **BIOLOGICAL:** 426c.Mod.Core-C4b 300 mcg
- **OTHER:** Placebo
- **BIOLOGICAL:** BG505

## Key facts

- **NCT ID:** NCT05471076
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-08-22
- **Primary completion:** 2025-12-23
- **Final completion:** 2026-05-21
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05471076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05471076, "Trial to Evaluate the Safety and Immunogenicity of Priming Regimens of 426c.Mod.Core-C4b and Optional Boost Regimen With HIV Trimer BG505 SOSIP.GT1.1 gp140, Both Adjuvanted With 3M-052-AF + Alum in Healthy, Adult Participants Without HIV". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05471076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*